

02.06.2023

Kategorie: Company

Rodenstock delivers robust FY 2022 results, based on further successful sales growth in its B.I.G. VISION™ product range

Rodenstock Group, a global innovation leader in Vision Care and high-quality manufacturer of biometric lenses, today announced its results for the financial year 2022.

- Solid like-for-like revenue growth of 4% to 505 million euros pro-forma sales in challenging market conditions
- Acquisition of Indo Optical and sale of eyewear business drive Rodenstock's transformation into a leading pure-play Med-Tech company
- Further growth expected in 2023, despite continued macro-economic uncertainty, based on commercial effectiveness and further product innovation

Munich, June 2023 – Rodenstock Group, a global innovation leader in Vision Care and high-quality manufacturer of biometric lenses, today announced its results for the financial year 2022. Driven by continuously growing demand for its B.I.G. VISION™ product portfolio of biometric progressive lenses as well as the the successful launch of its new B.I.G. NORM™ lense range in 2022, the group increased consolidated pro-forma net sales to 505 million euros (previous year 486 million euros on a like-for-like basis).

Rodenstock's B.I.G. VISION™ strategy remains at the core of the group's ambition to lead the paradigm shift in individual lenses and continue its transformation to become a leading lenses Med-Tech company. With its patented DNEye® technology, the company has further expanded its international business and its offering of individual biometric lenses in 2022. The acquisition of Indo Optical, which closed in September 2022, and the sale of its eyewear business to De Rigo, which was announced in December 2022, enable Rodenstock to fully focus on commercial effectiveness, global expansion and further lenses innovations over the coming years. The legal transfer of the eyewear business to De Rigo is expected to be completed in the second quarter of 2023.

Overall, fiscal year 2022 was impacted by the deterioration of the macro-economic environment following the invasion of Ukraine by Russia, leading to further disruption of international supply chains, rising inflation levels as well as substantial uncertainty among businesses and consumers. Rodenstock took decisive action and exited the Russian market swiftly by transferring the ownership of its Russian business to local management. Despite a slow-down in sales growth in the second half of 2022, Rodenstock Group generated recurring EBITDA of 118 million euros in 2022 down -4% compared to previous year on a like-for like basis, considering the transfer of the Russian business during the year and the deconsolidation of the eyewear business.

Marcus Desimoni, CEO of the Rodenstock Group, says: "Despite substantial market headwinds, we have successfully continued to execute on our B.I.G. VISION™ strategy and expanded our global lenses business. I would like to thank the entire team for their hard work and commitment over the past year. Strategic milestones such as the acquisition of Indo Optical and the sale of the eyewear business have provided the basis for further profitable growth in the coming years."

Dr. Mani Herold, CFO of the Rodenstock Group who joined on April 1st, adds: "2022 was marked by important strategic decisions for group. I am thrilled to be part of Rodenstock as we are entering the next phase of our transformation into a leading Med-Tech company and to support our worldwide organization in delivering strong

transformation into a leading Med-Tech company and to support our worldwide organization in delivering strong growth whilst focusing on superior financial performance and operational excellence.”

Marcus Desimoni took over the role as CEO of the Rodenstock Group in February 2023 having previously served as CFO of the company. On April 1st 2023, Dr. Mani Herold joined CFO of the Rodenstock Group, thus completing the Management Team. The leadership team will maintain the strategic direction of the group and will continue to invest into R&D as well as the group’s product and service portfolio as well as its state-of-the-art production facilities.

About Rodenstock:

Rodenstock Group is a worldwide leading manufacturer of high-quality ophthalmic lenses. With the philosophy "B.I.G. VISION™ FOR ALL", the lens manufacturer stands for a paradigm shift in the growth market of individual progressive lenses. The group, which was founded in 1877 with its headquarters in Munich, Germany, employs around 5,100 people worldwide and is represented with sales offices and distribution partners in more than 85 countries around the world. Rodenstock maintains 6 central production hubs to secure global supply. For more information, visit www.rodenstock.com/press.

Pressekontakt:

Rodenstock GmbH
Ralf Ellermann
Head of Global Marketing, Vice President
+49 172 8981 530
Ralf.Ellermann@rodenstock.com